Recent 8-K filings for STXS

• July 15, 2026, 5:37 PM ET other material materiality 0.65 negative item 8.01item 9.01

  Stereotaxis completes Robocath acquisition; files risk factors highlighting dilution and integration risks

  Acquisition closed July 7, 2026; issued 6,269,628 Closing Shares (including warrants) and up to $25M earnout.

• July 9, 2026, 8:13 AM ET M&A materiality 0.65 positive item 3.02item 7.01item 8.01item 9.01

  Stereotaxis completes acquisition of Robocath for ~$20M in cash and stock

  Deal valued at ~$20M in cash and common stock; earnout up to $25M based on regulatory/commercial milestones.

• May 15, 2026, 3:31 PM ET other material materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×3

  Stereotaxis annual meeting results: all three proposals approved by shareholders

  Elect David Benfer (52.2M for), Arun Menawat (49.5M for), Myriam Curet (52.7M for) as Class I directors.

• May 12, 2026, 4:10 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Stereotaxis reports Q1 revenue $6.3M, net loss $5.9M; guides FY26 rev >$40M; MAGiC FDA approved, Robocath acquisition

  Revenue $6.3M vs $7.5M YoY; net loss $5.9M; cash $14.6M, no debt.

• April 15, 2026, 7:59 PM ET M&A materiality 0.65 neutral item 1.01item 3.02item 7.01item 9.01 ◈ Material Agreements

  Stereotaxis to acquire Robocath for $20M initial plus up to $25M in earnouts

  Total consideration up to $45M: $20M upfront (cash/stock) plus earnouts of $10M (FDA approval) and $15M (commercial milestones).

• March 9, 2026, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01 ◈ Earnings Releases

  Stereotaxis reports Q4 2025 revenue $8.6M (+36% YoY); guides FY2026 revenue >$40M

  Q4 2025 revenue $8.6M (+36% YoY); system rev $3.3M, recurring $5.3M.

• November 12, 2025, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Stereotaxis Reports Q3 2025 Revenue of $7.5M, Net Loss $6.5M; Guides Q4 Revenue Above $9M

  Q3 2025 revenue totaled $7.5M, with system revenue of $1.9M and recurring revenue of $5.6M.

• August 29, 2025, 7:59 PM ET other material materiality 0.70 neutral item 1.01item 9.01

  Stereotaxis enters ATM equity agreement to sell up to $50M of common stock

  Agreement with Roth Capital Partners for at-the-market offering of up to $50M in common stock.

• August 7, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Stereotaxis Q2 revenue surges 95% to $8.8M; net loss narrows to $3.8M

  Revenue $8.8M (+95% YoY, +18% seq); system revenue $3.0M (vs $0.2M), recurring $5.8M (+35% YoY).

• July 17, 2025, 7:59 PM ET other material materiality 0.75 positive item 2.02item 8.01

  Stereotaxis pre-announces Q2 revenue $8.5-8.8M, up 90% YoY

  Revenue expected between $8.5M and $8.8M for Q2 2025, up ~15% sequentially and 90% YoY.

• July 17, 2025, 7:59 PM ET other material materiality 0.70 neutral item 1.01item 7.01item 9.01

  Stereotaxis announces $12.5M registered direct offering at $2.00/share

  Gross proceeds of $12.5M from sale of common stock at $2.00/share; initial closing of $8.5M (4.25M shares) expected July 18, 2025.

• May 19, 2025, 7:59 PM ET other materiality 0.10 neutral item 5.07

  Stereotaxis annual meeting elects directors Fischel and Levin, ratifies EY

  Quorum of 59% achieved with 63.8M shares represented out of 85.98M common plus 21.66M Series A votes.

• May 12, 2025, 7:59 PM ET earnings materiality 0.60 negative item 2.02item 9.01

  Stereotaxis Q1 revenue $7.5M (+9% YoY); recurring up 29%; operating loss widens to $5.9M

  Revenue $7.5M (+9% YoY); system revenue $2.0M, recurring revenue $5.5M (+29% driven by Map-iT catheters).

• March 3, 2025, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Q4 revenue up 39% to $6.3M; expects double-digit revenue growth in 2025

  Q4 2024 revenue $6.3M (+39% YoY); full year $26.9M (+0.4% YoY).

• November 12, 2024, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Stereotaxis Q3 revenue $9.2M, up 18% YoY; net loss $6.2M; cash $13.3M at Oct end

  Revenue $9.2M (+18% YoY); system revenue $4.4M, recurring $4.8M.

• August 12, 2024, 7:59 PM ET earnings materiality 0.60 negative item 2.02item 9.01

  Stereotaxis Q2 revenue down 43% to $4.5M; net loss $5.8M; expects H2 revenue >$14M

  Q2 revenue $4.5M vs $7.9M prior year; system revenue $0.2M due to hospital construction delays.

• August 2, 2024, 7:59 PM ET M&A materiality 0.55 neutral item 3.02item 8.01

  Stereotaxis closes acquisition of Access Point Technologies, issues 1.49M shares

  Acquisition of Access Point Technologies EP, Inc. (APT) completed on July 31, 2024.

• July 18, 2024, 7:59 PM ET leadership materiality 0.35 positive item 5.02item 7.01item 9.01 ◈ executive_change

  Stereotaxis appoints Nachum Shamir to board; former Luminex, Given Imaging CEO

  Nachum 'Homi' Shamir elected to Stereotaxis Board of Directors effective July 18, 2024.

• May 16, 2024, 7:59 PM ET M&A materiality 0.75 neutral item 1.01item 3.02item 5.07 ◈ Shareholder Votes ×4◈ Material Agreements ×2

  Stereotaxis acquires APT for stock; earnouts based on revenue & regulatory milestones

  Acquires APT, a diagnostic catheter maker, for stock consideration; earnouts tied to global revenue and US/EU regulatory milestones for robotically-navigated catheters.

• May 13, 2024, 7:59 PM ET other material materiality 0.70 neutral item 2.02item 8.01item 9.01 ◈ Earnings Releases

  Stereotaxis Q1 revenue $6.9M (+5% YoY); acquires Access Point Technologies for stock

  Q1 revenue $6.9M (+5% YoY); system revenue $2.6M, recurring $4.3M.

• March 4, 2024, 6:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01 ◈ Earnings Releases

  Stereotaxis Q4 revenue $4.6M, down 37% YoY; full year adjusted net loss $10.2M; guides Q1 2024 revenue ~$7M

  Q4 2023 revenue $4.6M vs $7.3M prior year; full year revenue $26.8M vs $28.1M.

• November 9, 2023, 6:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01 ◈ Earnings Releases

  Stereotaxis Q3 revenue $7.8M (+1% YoY); net loss $5.4M; cash $23M, no debt

  System revenue $3.5M from 2 Genesis systems; recurring revenue $4.3M (down 19% YoY, lost catheter royalties).

• August 10, 2023, 7:59 PM ET earnings materiality 0.60 positive item 2.02item 9.01 ◈ Earnings Releases

  Stereotaxis Q2 revenue $7.9M (+28% YoY), net loss $5.0M, cash $23.9M

  Revenue $7.9M, up 28% YoY; system revenue $3.3M (two Genesis systems), recurring revenue $4.6M.

• June 15, 2023, 7:59 PM ET regulatory materiality 0.65 neutral item 8.01item 9.01

  Stereotaxis to initiate first-in-human trial for MAGiC catheter after CE Mark clinical data request

  Notified body requests clinical data for MAGiC catheter CE Mark under EU MDR; prior submission included preclinical data.

• May 19, 2023, 7:59 PM ET other material materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×4

  Stereotaxis shareholders elect three directors, ratify EY, approve say-on-pay at 2023 annual meeting

  David W. Benfer elected with 39,528,692 votes for; Myriam Curet and Arun Menawat also elected.

• May 9, 2023, 7:59 PM ET earnings materiality 0.60 negative item 2.02item 9.01 ◈ Earnings Releases

  Stereotaxis Q1 revenue $6.5M, net loss $5.3M; reiterates double-digit growth outlook

  Revenue $6.5M vs $7.0M prior year; excluding catheter royalties, essentially flat.

• March 3, 2023, 6:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01 ◈ Earnings Releases ×2

  Stereotaxis 2022 revenue $28.1M (-20% YoY); net loss $4.2M in Q4; guides double-digit growth in 2023

  Q4 revenue $7.3M (down from $8.2M); full year revenue $28.1M (down from $35.0M).

• November 10, 2022, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01 ◈ Earnings Releases

  Stereotaxis Q3 2022 revenue $7.7M (-15% YoY); net loss widens to $4.9M

  Q3 2022 revenue $7.7M vs $9.1M prior year; system rev $2.4M, recurring $5.3M.

• August 9, 2022, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01

  Stereotaxis Q2 revenue $6.2M, down 32% YoY; net loss $5.2M; cash $35.1M

  Revenue $6.2M vs $9.1M YoY; system revenue $0.6M, recurring $5.6M.

• May 19, 2022, 7:59 PM ET other materiality 0.15 neutral item 5.07

  Stereotaxis shareholders elect directors, approve stock plans at annual meeting

  Elected Nathan Fischel (48.8M for) and Ross Levin (47.1M for) as Class III directors to serve until 2025.

• May 10, 2022, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01

  Stereotaxis Q1 revenue down 19% to $7.0M; net loss widens to $4.1M

  Revenue $7.0M vs $8.6M prior year; system revenue $1.6M, recurring $5.4M.

• March 3, 2022, 6:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Stereotaxis reports 32% revenue growth in FY2021; adjusted net loss widens to $1.4M

  Full-year 2021 revenue $35.0M (up 32% from $26.6M); Q4 revenue $8.2M (up 21%).

• November 12, 2021, 6:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Stereotaxis Q3 revenue $9.1M (+5% YoY); operating loss widens to $4.6M; sees 2022 system revenue doubling

  Revenue $9.1M (system $3.5M, recurring $5.3M); gross margin 52% with system margin 5% and recurring 86%.

• August 27, 2021, 7:59 PM ET litigation materiality 0.55 neutral item 8.01item 9.01

  Stereotaxis agrees to pay $675K to settle shareholder lawsuit over proxy disclosures

  Putative class action filed by Richard Barre alleged fiduciary duty breaches for CEO Performance Award proxy disclosure deficiencies.

• August 10, 2021, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Stereotaxis Q2 revenue $9.1M (+70% YoY); sees system revenue doubling in 2022

  Revenue up ~70% YoY to $9.1M; system revenue $2.7M, recurring $6.1M.

• July 26, 2021, 7:59 PM ET leadership materiality 0.55 positive item 5.02item 7.01item 9.01 ◈ executive_change

  Stereotaxis appoints Myriam Curet, Intuitive Surgical CMO, to board

  Appointed Myriam J. Curet, M.D., to Board effective July 22, 2021.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.80 · Median 0.65 · Most common event earnings

9 positive 8 negative 19 neutral

source · STXS on sec.gov